Northwest & Ethical Investments’s United Therapeutics UTHR Stock Holding History

Northwest & Ethical Investments’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.71M	Sell	3,156 -2,494	-44%	-$1.4M	0.04%	233
2026 Q1	$3.35M	Sell	5,650 -5	-0.1%	-$2.49K	0.08%	210
2025 Q4	$2.76M	Buy	5,655 +239	+4%	+$111K	0.06%	234
2025 Q3	$2.27M	Hold	5,416	–	–	0.05%	249
2025 Q2	$1.56M	Hold	5,416	–	–	0.04%	280
2025 Q1	$1.67M	Buy	5,416 +1,602	+42%	+$549K	0.05%	264
2024 Q4	$1.35M	Buy	3,814 +576	+18%	+$212K	0.04%	289
2024 Q3	$1.16M	Sell	3,238 -679	-17%	-$229K	0.03%	293
2024 Q2	$1.25M	Hold	3,917	–	–	0.04%	276
2024 Q1	$900K	Buy	+3,917	New	+$884K	0.03%	310

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Northwest & Ethical Investments's UTHR Position: Q2 2026 in Review

Northwest & Ethical Investments reduced its United Therapeutics (UTHR) stake by 44% in Q2 2026, selling an estimated $1.4M and leaving 3,156 shares worth $1.71M. The position accounts for 0.04% of the portfolio, ranked #233.

Northwest & Ethical Investments first reported a position in UTHR in Q1 2024 and has held it in 10 quarters since. The position peaked at $3.35M in Q1 2026. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Northwest & Ethical Investments held 3,156 shares of United Therapeutics worth $1.71M as of Q2 2026.
Northwest & Ethical Investments sold 2,494 United Therapeutics shares in Q2 2026, an estimated $1.4M.
United Therapeutics made up 0.04% of Northwest & Ethical Investments's portfolio in Q2 2026, its #233 holding.
Northwest & Ethical Investments first reported a position in United Therapeutics in Q1 2024 and has held it in 10 quarters since.
Northwest & Ethical Investments's United Therapeutics position peaked at $3.35M in Q1 2026.
878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Northwest & Ethical Investments's 13F filing for Q2 2026, filed 13 Aug 2026.